论文部分内容阅读
目的分析雌激素受体(ER)、孕激素受体(PR)和人类表皮生长因子受体2(HER-2)三阴性乳腺癌的临床病理特征和预后。方法经病理确诊的乳腺癌患者613例分为三阴性乳腺癌组(A组,122例)和非三阴性乳腺癌组(B组,491例)。比较两组患者的临床病理特征、复发和远处转移及生存情况。结果 A组髓样癌发生率21.3%,组织学Ⅲ级占60.6%,p53基因阳性表达率73.7%,均明显高于B组的5.9%,30.9%,40.9%(P<0.05);A组淋巴结转移率高于B组(49.2%vs.40.1%)P<0.05);A组局部复发率和肝、肺转移率均显著高于B组(P<0.05)。生存分析显示,A组5年无瘤生存率和5年总生存率分别为65%和81%,均显著低于B组的76%和88%(P<0.05)。结论三阴性乳腺癌具有特定的临床特征,无瘤生存率和总生存率明显低于非三阴性乳腺癌患者。
Objective To analyze the clinicopathological features and prognosis of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER-2) triple negative breast cancer. Methods Totally 613 breast cancer patients diagnosed by pathology were divided into triple negative breast cancer group (A group, 122 cases) and non triple negative breast cancer group (B group, 491 cases). The clinicopathological characteristics, recurrence, distant metastasis and survival of the two groups were compared. Results The incidence of medullary carcinoma in group A was 21.3%, histologically grade Ⅲ was 60.6%, and the positive expression rate of p53 was 73.7%, which was significantly higher than that in group B (5.9%, 30.9%, 40.9%, P <0.05) The rate of lymph node metastasis in group A was higher than that in group B (49.2% vs. 40.1%, P <0.05). The local recurrence rate and liver and lung metastasis rate in group A were significantly higher than those in group B (P <0.05). Survival analysis showed that 5-year disease-free survival rate and 5-year overall survival rate in group A were 65% and 81%, respectively, which were significantly lower than 76% and 88% in group B (P <0.05). Conclusion Triple negative breast cancer has specific clinical features, tumor-free survival rate and overall survival rate was significantly lower than non-triple negative breast cancer patients.